Effects of intragastric balloon on obesity in obese Korean women for 6 months post removal

Hyeon-Ju Pak; Ha-Neul Choi; Hong-Chan Lee; Jung-Eun Yim

doi:10.4162/nrp.2021.15.4.456

Journal List > Nutr Res Pract > v.15(4) > 1147316

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Pak, Choi, Lee, and Yim: Effects of intragastric balloon on obesity in obese Korean women for 6 months post removal

Original Research

Nutrition Research and Practice 2021; 15(4): 456-467.

Published online: 8 February 2021

DOI: https://doi.org/10.4162/nrp.2021.15.4.456

Effects of intragastric balloon on obesity in obese Korean women for 6 months post removal

Hyeon-Ju Pak^1,^*

, Ha-Neul Choi^1,^*

, Hong-Chan Lee²

, Jung-Eun Yim^1,³

¹Department of Food and Nutrition, Changwon National University, Changwon 51140, Korea.

²Clinic B, Seoul 06035, Korea.

³Interdisciplinary Program in Senior Human Ecology (BK21 Four Program), Changwon National University, Changwon 51140, Korea.

Corresponding Author: Jung-Eun Yim. Department of Food and Nutrition, Changwon National University, 20 Changwondaehak-ro, Uichang-gu, Changwon 51140, Korea. Tel. +82-55-213-3517, Fax. +82-55-281-7480, jeyim@changwon.ac.kr

Equal contributor:

^*These authors contributed equally to this study.

Received 10 September 2020 Revised 15 December 2020 Accepted 7 January 2021

The Korean Nutrition Society and the Korean Society of Community Nutrition

https://creativecommons.org/licenses/by-nc/4.0/

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

BACKGROUND/OBJECTIVES

The prevalence of morbid obesity in Korean women has consistently been increasing, while the overall prevalence rate of obesity in Korean women seems to be stable. In addition to bariatric surgery, intragastric balloons (IGBs), as a nonsurgical therapy, have been reported to be effective in weight loss. However, the beneficial effects of IGB in Korean women with obesity have not been fully investigated. The aim of this study was to evaluate the changes in fat mass in Korean women with obesity who had undergone IGB treatment for 6 mon.

SUBJECTS/METHODS

Seventy-four women with obesity (body mass index [BMI] ≥ 25.0 kg/m²) were recruited. Clinical data, including general information, comorbidities with obesity, anthropometric data, and changes in the body fat composition before and after IGB treatment, were obtained from the subjects.

RESULTS

Most subjects had one or more comorbidities, such as osteoarthropathy and woman's disease, and had poor eating behaviors, including irregular mealtimes, eating quickly, and frequent overeating. Body composition measurements showed that weight, fat mass, and waist-hip circumference ratio decreased significantly at 6 mon after IGB treatment. In particular, women with morbid obesity (BMI ≥ 30 kg/m²) showed 33% excess weight loss. There was no significant difference in skeletal muscle mass and mineral contents after IGB treatment.

CONCLUSIONS

This study suggested that 6 mon of IGB treatment can be a beneficial treatment for obesity without muscle mass and bone mineral loss.

Go to :

Keywords: Obesity, gastric balloon, eating habits, skeletal muscle

INTRODUCTION

The emerging obesity prevalence in developing countries worldwide is alarming, including that in Korea. In 2016, 40% of women aged 18 years and above were overweight and 15% of women were obese worldwide [1]. According to the National Center for Health Statistics reports, the age-adjusted prevalence of severe obesity among adults represented 6.9% of men and 11.5% of women [2]. The prevalence of overweight and obesity was similar in men and women, whereas the prevalence of severely obese women was approximately twice as high as that of men. The increasing rate of overweight and obesity in Korea, as well as Western societies, results in a serious public health problem. The prevalence of obesity has rapidly increased between 1998 (26.0%) and 2018 (34.6%) in Korean adults. The prevalence of obesity remained relatively stable from 25.2% in 2008 to 25.5% in 2018 for women, while the prevalence in men sharply increased from 2005 (35.3%) to 2018 (42.8%) [3]. Despite the stable findings on the overall prevalence rate of obesity in Korean women, a consistent increase in morbid obesity (body mass index [BMI] ≥ 30.0 kg/m²) from 3.5% in 2008 to 4.9% in 2018 has been recorded [3 4].

Increased prevalence of obesity leads to a wide spectrum of diseases, including hyperlipidemia, metabolic syndrome, hypertension (HTN), cardiovascular diseases, type 2 diabetes mellitus (T2DM), cancer, and depression, without specific symptoms [5 6]. By losing approximately 5–10% of body weight, HTN, insulin resistance, the risk of osteoarthritis, cancers, and other hazards for chronic diseases can be significantly improved [7 8]. In 2019, the incidence rates of T2DM, HTN, myocardial infarction, and stroke consistently increased as BMI increased between ages 20–39 years in Koreans [5]. Seo et al. [5] also reported that T2DM, HTN, and hyperlipidemia were significantly higher in individuals with BMI ≥ 25 kg/m². Additionally, the detrimental consequences of being obese have been found to be especially harmful in women, elevating risks for mental health conditions, polycystic ovary syndrome, endometriosis, and cancer, including endometrial and breast cancer [9 10 11]. Therefore, it is important to prevent and manage obesity.

The final goal of obesity treatment is to achieve and maintain an ideal body weight (IBW). There are several methods that have been used to treat obesity, such as lifestyle modifications (diet and behavior), exercise, medications, endoscopic procedures, and surgery [12]. Diet and behavior modification and exercise are conventional treatment methods, but many studies reported that lifestyle modifications might fail at sustaining weight loss [13 14 15]. Some researchers also suggest that traditional therapy is not very effective in T2DM patients with severe obesity [16]. Diet and behavior modifications as well as exercise, with or without medication, is the best initial treatment method; however, methods such as bariatric surgery or endoscopic procedures are needed for individuals with severe obesity [17]. Bariatric surgery, including gastric bypass (GBP), adjustable gastric band, sleeve gastrectomy, and duodenal switch, has been reported to be effective in the long term for weight loss. Despite these advantages, surgery should be considered only for patients with BMI ≥ 35 kg/m² who have failed nonsurgical methods (with or without medications) and who have obesity-related complications. Further, bariatric surgery has limitations: it is an expensive and invasive procedure and may cause serious complications such as nutritional shortages, gallstones, ulceration, and hernias [18].

Intragastric balloons (IGBs), which are a form of nonsurgical therapy, are designed for weight loss and have minimal side effects compared with bariatric surgery [19]. The Garren-Edwards Gastric Bubble was the first US Food and Drug Administration-approved IGB in 1985 [20]. IGBs that were more effective in promoting weight loss have consistently been developed over the last 20 years. Typically, an IGB is filled with air or saline solution of 400–700 mL and placed in the stomach to occupy space and reduce gastric capacity, resulting in weight loss [21]. The most common complications of IGBs include vomiting, nausea, and a treatment duration of 6 mon; however, treatment side effects are minimal compared with those of bariatric surgery. The End-Ball®, approved by the Ministry of Food and Drug Safety, and the most generally used IGB treatment in Korea, is made of smooth spherical elastic polyurethane [22].

IGB could play a beneficial role in reducing obesity by reducing stomach volume with minimal side effects compared with surgery. However, the beneficial effects of IGB in Korean women have not been fully investigated. Therefore, this study aimed to evaluate the effects of IGB treatment for 6 mon on obesity in Korean women.

Go to :

SUBJECTS AND METHODS

Subjects and study design

This clinical study was a retrospective study, using subjects' medical records. We analyzed data from 74 female patients with obesity (BMI ≥ 25 kg/m²) who received IGB treatment. The study included data collected during the period from February 2016 to July 2017. Data retrieved from subjects' medical records included information on age, sex, weight, height, body composition, comorbidities with obesity, and health-related behaviors. We analyzed their medical records before IGB and 6 mon after IGB. Subjects who had a BMI of < 25 kg/m², were under 18 years of age, were males, or had no medical records before and after IGB were excluded from the study. Power calculations to determine the required sample size were performed with GPower (version 3.1.) using an alpha value of 0.05 and a power of 95%. This retrospective medical record review was approved by Changwon National University's Institutional Review Board (IRB) (IRB No. 1040271-201711-HR-030). Patients' medical records were analyzed before IGB and at 1, 3, and 6 mon after IGB treatment.

Anthropometric analysis

Anthropometric measurements were obtained from all subjects. Height and weight were measured with a digital scale. BMI was calculated by dividing the subject's weight (kg) by the square of the subject's height (m²). Body fat mass (BFM; kg), percent body fat (PBF; %), and skeletal muscle mass (SMM; kg) were measured using bioimpedance analysis (InBody 3.0; Biospace, Seoul, Korea). Waist circumference (WC) and hip circumference (HC) were measured with a flexible and substantial tape. Waist-to-hip ratio (WHR) was calculated as the WC divided by HC. Anthropometric measurements and body composition data were measured before and 1, 3, and 6 mon after IGB treatment. Percentage of excess weight loss (%EWL) was generally calculated using the formula: %EWL = (preoperative weight – initial weight) ÷ (initial weight − IBW) ×100.

General characteristics, health-related lifestyle, and experience of nonsurgical treatments

For all the subjects, general characteristics, lifestyle, and experience of nonsurgical treatments were analyzed using questionnaires and medical interviews. The general characteristics of age (20–29, 30–39, 40–49, or ≥ 50 years), marital status (married/unmarried), and occupation (manual worker, office clerk, student, or unemployed) were assessed. The health-related lifestyles were categorized as follows: alcohol consumption (yes, no), smoking status (yes, no), and complication-related obesity (osteoarthropathy, women-specific diseases, sleep disturbance, diabetes, psychical disorder, HTN, asthma, fatty liver, and others). Nonsurgical treatments were classified as diet therapy, exercise, behavior modification, pharmacotherapy, and others.

Eating habits questionnaire

The eating habit section was designed to investigate dietary patterns related to meal frequency (irregular, once, 2 times, or 3 times per day), meal time (fixed time, sometimes irregular, or irregular), meal speed (> 20, 10–20, or within 10 min), and overeating (≤ 1 time, 2–3 times, or ≥ 4 times per week). The eating habits questionnaires were administered to the subjects once during the study, and subjects were asked about their dietary behaviors.

Statistical analysis

All data are represented as means ± SD, and the statistical significance was set at P < 0.05. The data from the questionnaire surveys were compared using the χ² test. In addition, the changes in weight and body composition determined before and at 1, 3, and 6 mon after IGB treatment were analyzed using a 1-way repeated measures analysis of variance. The collected data were analyzed using IBM SPSS Statistics version 24 software package (IBM Corp., Armonk, NY, USA).

Go to :

RESULTS

General characteristics

A total of 74 subjects were enrolled in this study; their general and health-related lifestyle characteristics at baseline are shown in Table 1. The mean age was 34.7 years. The mean BMI was 31.0 ± 4.2 kg/m². A total of 43.2% of the subjects had age and BMI within 30–39 years and 25–30 kg/m², respectively. Among the subjects, 32 (43.2%), 28 (37.8%), and 14 (18.9%) met the BMI criteria for obesity, severe obesity, and morbid obesity, respectively. Subjects who reported as unmarried constituted 63.5% of the sample, and most subjects (72.5%) were office clerks. Regarding alcohol consumption, 60.8% of the subjects responded “yes,” and 39.2% responded otherwise. The smoking response rate for “no” was 70.3%.

Table 1

General characteristics of the subjects at baseline

Variables		Total (n=74)
Age (yrs)		34.74 ± 8.84
	20–29	23 (31.1)
	30–39	32 (43.2)
	40–49	13 (17.6)
	≥ 50	6 (8.1)
Height (cm)		163.37 ± 5.41
Weight (kg)		82.74 ± 12.70
Body mass index (kg/m²)		30.95 ± 4.21
	25–29.9	32 (43.2)
	30–34.9	28 (37.8)
	35–39.9	12 (16.2)
	≥ 40	2 (2.7)
Marital status
	Married	27 (36.5)
	Not married	47 (63.5)
Occupation
	Manual worker	12 (17.4)
	Office clerk	50 (72.5)
	Students	6 (7.9)
	Unemployed	1 (1.3)
Alcohol drinking
	Yes	45 (60.8)
	No	29 (39.2)
Smoking
	Yes	22 (29.7)
	No	52 (70.3)
Complication		42 (56.8)
	Osteoarthropathy	15 (20.3)
	Woman disease	14 (18.9)
	Sleep disturbance	5 (6.8)
	Diabetes	5 (6.8)
	Psychical disorder	5 (6.8)
	Hypertension	5 (6.8)
	Asthma	4 (5.4)
	Fatty liver	4 (5.4)
	Others	3 (4.1)

Values are presented as mean ± SD or number (%). The data from the questionnaire surveys were compared using the χ² test.

Data on the subjects' experience of nonsurgical treatments at baseline are shown in Table 2. According to the questionnaire, 42 (56.8%) subjects had obesity-related complications. Osteoarthropathy (20.3%) and women-specific diseases (18.9%) were more frequently found in these subjects. Among the subjects with complications, 5% of the respondents indicated sleep disturbance, diabetes, psychical disorder, and HTN. Asthma, fatty liver, and others each accounted for 4% of the total responses. All subjects had tried nonsurgical therapy, such as pharmacotherapy (89.2%), exercise (85.1%), and diet modifications (71.6%, Table 2).

Table 2

Experience of nonsurgical treatments of the subjects at baseline

Variables		Total (n=74)
Weight control experience
	Yes	74 (100.0)
Diet therapy		53 (71.6)
	Exercise therapy	63 (85.1)
	Behavior modification therapy	1 (1.4)
	Pharmacotherapy	66 (89.2)
	Others	24 (32.4)

Values are presented as number (%). Multiple choices are available. The data from the questionnaire surveys were compared using the χ² test.

Eating habits

Results about the eating habits of study subjects at baseline are shown in Table 3. Regarding the number of meals per day, 35.6% and 42.4% of the subjects reported “Irregular” and “2 times,” respectively. Only 20.3% had meals 3 times per day. Furthermore, the mealtime response rate for “irregular” was 49.3%, whereas 35.8% and 14.9% of subjects had “sometimes irregular” and “fixed” mealtimes, respectively. Most (46.5%) subjects finished their meals within 10 min, whereas 39.4% and 14.1% of the subjects finished their meals within 10–20 min and ≥ 20 min, respectively. Approximately 50% of the subjects reported overeating 2–3 times per week, and 44.8% overate ≥ 4 times per week. Thus, most subjects tended to eat at irregular times, ate fast (within 10 min), and overeat 2–3 times per week.

Table 3

Eating habits of subjects at baseline

Eating habits		Total (n = 74)
Meal number of times
	Irregular	21 (35.6)
	1 time	1 (1.7)
	2 times	25 (42.4)
	3 times	12 (20.3)
Mealtime
	Fixed time	10 (14.9)
	Sometimes irregular	24 (35.8)
	Irregular	33 (49.3)
Meal speed (min)
	More 20	10 (14.1)
	10–20	28 (39.4)
	Within 10	33 (46.5)
Overeating (per week)
	Rarely (≤ 1 time)	2 (3.0)
	Sometimes (2–3 times)	35 (52.2)
	Often (≥ 4 times)	30 (44.8)

Values are presented as number (%). The data from the questionnaire surveys were compared using the χ² test.

Changes in body composition in subjects

Body composition analyses before and after IGB are presented in Table 4. The results from anthropometrics indices before and after IGB showed significant reduction in body weight, BMI, BFM, PBF, and WHR at 6 mon after IGB treatment. There were no statistically significant differences in SMM and mineral contents after IGB treatment. The rate of weight loss, BFM loss, and WHR loss were 8.8%, 14.3%, and 2.6%, respectively, at 6 mon after IGB treatment. In particular, the decrease rate of the PBF was highest among the anthropometric measurements. The decreasing rate of PBF was significantly higher from 1 mon to 3 mon after IGB, whereas the decreasing rate of body weight and WHR were significantly higher from baseline to 1 mon after IGB (Fig. 1). Particularly, severely obese subjects (35 kg/m² ≤ BMI < 40 kg/m²) showed greater weight loss (−11.7%, Fig. 2).

Fig. 1

Percentage changes in weight, body fat, and waist-hip ratio at 1, 3, and 6 mon after intragastric balloon treatment. All values are presented as mean ± SD, analyzed using repeated measures analysis of variance. Values in a line with different superscript letters are significantly different at P < 0.05.

WHR, waist-hip ratio.

Fig. 2

Percentage changes in weight according to baseline BMI.

BMI, body mass index.

Table 4

Changes in body composition at baseline and after IGB treatment

Variables	Duration
Variables	Baseline (n = 74)	1 mon (n = 74)	3 mon (n = 74)	6 mon (n = 74)
Weight (kg)	82.74 ± 12.70^a	78.93 ± 12.26^ab	77.66 ± 11.75^ab	74.97 ± 12.22^b
BMI (kg/m²)	30.95 ± 4.21^a	29.62 ± 3.98^ab	29.21 ± 4.03^ab	28.24 ± 3.90^b
Body fat (kg)	34.97 ± 9.18^a	32.86 ± 8.93^ab	31.02 ± 8.64^ab	29.20 ± 8.81^b
PBF (%)	41.70 ± 5.53^a	41.06 ± 5.71^ab	39.37 ± 6.14^ab	38.30 ± 5.94^b
WHR (%)	0.94 ± 0.04^a	0.93 ± 0.04^ab	0.92 ± 0.44^ab	0.91 ± 0.76^b
SMM (kg)	26.14 ± 0.49	25.38 ± 0.46	25.19 ± 0.53	24.86 ± 0.47
Protein (kg)	9.38 ± 1.03^a	9.04 ± 1.02^ab	9.15 ± 1.10^ab	8.96 ± 1.00^b
ICW (L)	21.70 ± 2.38^a	20.90 ± 2.35^ab	21.16 ± 2.55^ab	20.74 ± 2.33^b
ECW (L)	13.63 ± 3.42	12.84 ± 1.43	13.01 ± 1.51	12.78 ± 1.42
Mineral (kg)	3.40 ± 0.40	3.31 ± 0.37	3.31 ± 0.37	3.29 ± 0.41

All values are expressed as mean ± SD, analyzed using repeated measures analysis of variance. Means in the same row not sharing a common letter are significantly different at P < 0.05.

BMI, body mass index; PBF, percent body fat; WHR, waist-hip ratio; SMM, skeletal muscle mass; ICW, intracellular water; ECW, extracellular water.

Changes in body composition according to degree of obesity

Changes in BMI between baseline and after 6 mon in morbidly obese (BMI ≥ 30.0 kg/m²) subjects are presented in Table 5. The rate of morbidly obese subjects decreased after IGB treatment from 56.8% to 36.5%. The %EWL of morbidly obese subjects (BMI ≥ 30 kg/m²) was presented at 33.0 ± 28.4%.

Table 5

Percentage changes in initially morbidly obese women and excess weight loss

Variables	Baseline (n = 42)	After 6 mon (n = 27)
Severe obesity	56.8%	36.5%
%EWL	33.0 ± 28.4%

Values are presented as number (%).

%EWL, percentage of excess weight loss.

Go to :

DISCUSSION

During the past few decades, the prevalence rates of obesity have been rapidly increasing worldwide, reaching a critical point. According to the World Health Organization, over 650 million (13%) of the world's adult population were obese in 2016 [1]. Thus, obesity has become a serious public health problem worldwide and can result in obesity-related diseases. We investigated the beneficial effects of IGB treatment on obesity in Korean women with obesity. Seventy-four women were recruited, and their general characteristics, eating habits, health related lifestyle, and body composition were analyzed.

Because of the analysis of general characteristics and health-related lifestyle factors, more than half of the subjects had one or more comorbidities, such as osteoarthropathy and woman’s disease. Osteoarthropathy is a syndrome that includes clubbing of the toes and fingers, periostitis of joint and long bones (radius, distal tibia, femur), and osteoarthritis [23]. Obesity is characterized by a systemic low-grade inflammatory status, leading to the development of metabolic diseases [24]. Obesity and pathogenesis of osteoarthropathy are not known; imbalanced adipokine expression leading to the remodeling and destruction of joint tissue has been reported [25 26]. Reyes et al. [27] reported that as the BMI increased, the risk of knee osteoarthritis increased. Compared to normal weight, as the degree of obesity increased, the risk of irregular menstruation increased; at 20–24 years, the risks increased by 33.3%. BMI was also strongly associated with the risk of breast cancer among postmenopausal women. Maternal complications with increase in BMI in women [28]. Our results are in line with those of previous studies that showed that increase in obesity greatly elevated the risk of obesity-related complications [29 30]. Thus, weight loss after IGB treatment is thought to effectively alleviate obesity, suggesting an improvement in osteoarthritis and women's disease. Crea et al. [29] reported that the incidence of T2DM, hypertriglyceridemia, hypercholesterolemia, and HTN at 1 year of follow-up after IGB was significantly lower than before IGB. Another previous study found that diastolic blood pressure significantly decreased after IGB removal [30]. Similar improvements in fasting blood glucose, total cholesterol, triglyceride (TG), C-reactive protein, and hemoglobin A1C (HbA1c) levels were also found in other studies of IGB in addition to significantly increased quality of life as compared to baseline [31]. Therefore, IGB treatment may be effective in improving the comorbidities of obesity, including metabolic syndrome.

The lack of exercise, sedentary lifestyle, and unhealthy eating habits are reported as the main causes of excess body fat accumulation [32 33]. In a study by Hassan et al. [32], most obese and overweight Egyptian women, were engaged in health risk behaviors and unhealthy dietary patterns (the low intake of fruits, vegetables, and milk, the increasing consumption of snacks, sweets, salts, and soft drinks). Korean children in the overweight group were also significantly more likely to overeat and ate rapidly compared with the normal group [33]. In a study by Kang et al. [34], regarding the eating habits, high response rates for “Consumed meal quickly (< 10 min),” “Preference of oily foods”, and “A tendency to eat until the stomach is full” were observed in metabolically abnormal, obese women. Our study also showed that most obese subjects had negative eating habits, including eating at irregular times, eating fast (within 10 min), and overeating frequently (2–3 times per week), which was consistent with previous studies [20 32 33 34].

IGB with a volume of 400 mL or greater may also lead to feelings of satiety by delaying gastric emptying and finally reducing their food intake [21]. Additionally, evidence suggests that IGB suppresses food intake through the vagal signaling by modulated gastric mechanoreceptors [35]. The Bioenteric intragastric balloon (BIB), also known as ORBERA, has been most widely used in IGB treatment. BIB is made of silicone, which is thicker than polyethylene, and the balloon volume is, thus, significantly bigger and has a high incidence of complications [36]. Buzga et al. [36] reported a mean weight loss of 13.9 kg with a %EWL of 37.9% in 20 patients in 6 mon after End-Ball treatment. Keren and Rainis [37] reported a mean weight loss of 23.5 kg and a %EWL of 39.2% in 114 subjects who were treated with the End-Ball; the weight loss significantly continued for 1 year after End-Ball removal. Some researchers suggested classifying the outcome of IGB into three categories based on the %EWL: %EWL < 20, unsatisfying outcome; %EWL of 20–50, good outcome; and %EWL > 50, very good outcome [38 39]. In this study, we also found that body weight, body fat, and WHR significantly decreased at 6 mon after IGB treatment. In particular, patients with morbid obesity (BMI ≥ 30 kg/m²) showed a mean %EWL of 33.0%.

The results of this study also showed that SMM and mineral contents were not significantly different after IGB treatment with adverse reduction in BFM. Obesity is negatively associated with muscle mass, which detrimentally affects muscle function. Obesity may induce an increase in intramuscular adipose tissue resulting in impaired muscle strength and mobility [40]. Reduced muscle function is a crucial predictor of serious problems, including the restriction of physical activity, mobility disability, hip fracture, falls, and increased mortality rate [41]. Thus, subjects with obesity also tended to have an increased risk of fracture in peripheral sites [40]. Bone mineral loss can accelerate the risk of hip fracture and osteoporosis in women. Nevertheless, excessive weight loss can also add to the increasing risk of fracture by inducing muscle mass loss and imbalance in bone metabolism [42]. Thus, maintenance of muscle and bone mineral should be the focus of therapeutic strategies for obesity. Previous studies have reported that bone mineral contents significantly decreased after bariatric surgery. Bone mineral density (BMD) at the hip tended to decline to an extent of 1 year after GBP [43]. Carrasco et al. [44] reported that GBP results in a significant loss in BMD with changes in body composition in women with obesity. Therefore, IGB, which has fewer side effects, muscle mass loss, and mineral reduction, is considered to play a key role in obesity treatment as compared with pharmacotherapy and surgery, especially in patients with mild to moderate obesity who failed previous treatment methods.

However, this study had some limitations. First, we did not investigate the improvement of obesity-related complications after IGB and metabolic parameters before and after IGB. Therefore, we could not assess how IGB helps with the improvement of metabolic status related obesity, maintenance of SMM, and bone mineral with sustained weight loss in subjects with obesity. Second, the time of exercise or physical activity on weekends was not included in the questionnaire survey. Third, we did not investigate the eating habits and health-related lifestyles of subjects after IGB. Fourth, we did not investigate the side effects of IGB. IGB may result in a few side effects such as nausea, heart burn, and gastric ulcers with bleeding and erosions [30]. However, IGB is reported to have a lower risk of complications than bariatric surgery.

Of the patients with bariatric surgery, 20-30% do not achieve weight loss [45 46]. Approximately 20-25% of patients undergoing bariatric surgery can also achieve weight loss over a period of 10 years [46]. Although IGB has also been shown to be effective in achieving weight loss, only 22% of the patients with IGB maintained the weight loss in relation to their initial weight at the end of IGB removal [34]. Crea et al. [29] reported that weight regain generally presented during follow-up after IGB removal. Thus, weight regain remains a risk for all severely obese patients after IGB and bariatric surgery.

Maekawa et al. [47] investigated the effectiveness of combining a low-carbohydrate diet (< 120 g carbohydrate/day) versus a calorie-restricted diet (IBW × 25) with IGB treatment. At 1 year after IGB, the %EWL of both groups were shown as 49.9 ± 60.0 and 33.1 ± 27.0, respectively, showing an excellent weight loss effect. The TG, high-density lipoprotein cholesterol, saturated fatty acid, and HbA1c levels of the low-carbohydrate diet group were significantly decreased lower than before IGB. Weight regain was also significantly lower in the low-carbohydrate diet group than in the calorie-restricted diet group. Thus, dietary modulation is essential for preventing weight regain, and carbohydrate restriction is considered to be more effective in maintaining weight loss after IGB.

Papalazarou et al. [48] reported that the effect of weight loss varies according to eating habit modification and physical activity, even though patients would have undergone the same surgery for obesity. Subjects who are extremely obese have been reported to have poor eating habits, such as frequent (4 days or more per week) consumption of high-fat and sweet foods/drinks like hamburgers, sausages, chocolate, soft drinks, and ice cream before surgery [49]. Therefore, to increase weight loss after IGB treatment, it is necessary to correct bad eating habits before IGB treatment, and for this, continuous diet and health-related lifestyle modifications along with education on nutrition is required.

In conclusion, most Korean women with obesity had comorbidities related with obesity, such as osteoarthropathy and woman’s disease, and had negative eating habits. Additionally, IGB can be of beneficial effect in ameliorating obesity without adversely decreasing SMM and bone mineral. We suggest that further studies be conducted to evaluate the changes in eating habits and metabolic and inflammatory biomarkers in Korean women with obesity who have received IGB treatment.

Go to :

Notes

Funding: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number) (NRF-2016R1D1A1B03935660).

Conflict of Interest: The authors declare no potential conflicts of interests.

Author Contributions:

Conceptualization: Yim JE, Lee HC.
Data curation: Pak HJ, Lee HC.
Formal analysis: Pak HJ, Choi HN.
Funding acquisition: Yim JE.
Supervision: Yim JE.
Writing - original draft: Pak HJ, Choi HN.
Writing - review & editing: Yim JE.

Go to :

References

1. World Health Organization. Fact sheets: obesity and overweight [Internet]. Geneva: World Health Organization;2020. cited 2020 April 1. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

2. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020; 360:1–8.

3. Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention. Korea Health Statistics 2018: Korea National Health and Nutrition Examination Survey. Sejong: Korea Centers for Disease Control and Prevention;2020.

4. Shin HY, Kang HT. Recent trends in the prevalence of underweight, overweight, and obesity in Korean adults: the Korean National Health and Nutrition Examination Survey from 1998 to 2014. J Epidemiol. 2017; 27:413–419. PMID: 28420559.

5. Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, Kim BY, Kim YH, Kim WJ, Kim EM, et al. 2018 Korean society for the study of obesity guideline for the management of obesity in Korea. J Obes Metab Syndr. 2019; 28:40–45. PMID: 31089578.

6. Preiss K, Brennan L, Clarke D. A systematic review of variables associated with the relationship between obesity and depression. Obes Rev. 2013; 14:906–918. PMID: 23809142.

7. Baranowski T, Cullen KW, Nicklas T, Thompson D, Baranowski J. Are current health behavioral change models helpful in guiding prevention of weight gain efforts? Obes Res. 2003; 11(Suppl):23S–43S. PMID: 14569036.

8. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med. 1992; 116:535–539. PMID: 1543306.

9. Molyneaux E, Poston L, Ashurst-Williams S, Howard LM. Obesity and mental disorders during pregnancy and postpartum: a systematic review and meta-analysis. Obstet Gynecol. 2014; 123:857–867. PMID: 24785615.

10. Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, Ochs-Balcom HM, Thomson CA, Caan BJ, Tinker LF, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women's health initiative randomized clinical trials. JAMA Oncol. 2015; 1:611–621. PMID: 26182172.

11. Alhusen JL, Ayres L, DePriest K. Effects of maternal mental health on engagement in favorable health practices during pregnancy. J Midwifery Womens Health. 2016; 61:210–216. PMID: 26849176.

12. Ruban A, Stoenchev K, Ashrafian H, Teare J. Current treatments for obesity. Clin Med (Lond). 2019; 19:205–212. PMID: 31092512.

13. Caudwell P, Hopkins M, King NA, Stubbs RJ, Blundell JE. Exercise alone is not enough: weight loss also needs a healthy (Mediterranean) diet? Public Health Nutr. 2009; 12:1663–1666. PMID: 19689837.

14. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014; 22:5–13. PMID: 24307184.

15. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009; 360:859–873. PMID: 19246357.

16. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012; 366:1577–1585. PMID: 22449317.

17. Daniel S, Soleymani T, Garvey WT. A complications-based clinical staging of obesity to guide treatment modality and intensity. Curr Opin Endocrinol Diabetes Obes. 2013; 20:377–388. PMID: 23974764.

18. Nguyen NT, Vu S, Kim E, Bodunova N, Phelan MJ. Trends in utilization of bariatric surgery, 2009–2012. Surg Endosc. 2016; 30:2723–2727. PMID: 26659240.

19. Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology. 2017; 152:1791–1801. PMID: 28192103.

20. Gleysteen JJ. A history of intragastric balloons. Surg Obes Relat Dis. 2016; 12:430–435. PMID: 26775045.

21. Tate CM, Geliebter A. Intragastric balloon treatment for obesity: review of recent studies. Adv Ther. 2017; 34:1859–1875. PMID: 28707286.

22. Choi SJ, Choi HS. Various intragastric balloons under clinical investigation. Clin Endosc. 2018; 51:407–415. PMID: 30257544.

23. Cecil RL, Goldman L, Schafer AI. Goldman's Cecil Medicine. 24th ed. Philadelphia (PA): Saunders;2012.

24. O'Rourke RW. Inflammation in obesity-related diseases. Surgery. 2009; 145:255–259. PMID: 19231576.

25. Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol. 2011; 7:528–536. PMID: 21808287.

26. Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum. 2000; 43:953–968. PMID: 10817547.

27. Reyes C, Leyland KM, Peat G, Cooper C, Arden NK, Prieto-Alhambra D. Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: a population-based cohort study. Arthritis Rheumatol. 2016; 68:1869–1875. PMID: 27059260.

28. Korean Society for the Study of Obesity. Obesity fact sheet for Koreans [Internet]. Seoul: Korean Society for the Study of Obesity;2017. cited 2020 August 25. Available from: http://www.kosso.or.kr/popup/obesity_fact_sheet.html.

29. Crea N, Pata G, Della Casa D, Minelli L, Maifredi G, Di Betta E, Mittempergher F. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009; 19:1084–1088. PMID: 19506981.

30. Suchartlikitwong S, Laoveeravat P, Mingbunjerdsuk T, Vutthikraivit W, Ismail A, Islam S, Islam E. Usefulness of the ReShape intragastric balloon for obesity. Proc Bayl Univ Med Cent. 2019; 32:192–195. PMID: 31191125.

31. Mui WL, Ng EKW, Tsung BYS, Lam CH, Yung MY. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2010; 20:1128–1132. PMID: 19015930.

32. Hassan NE, Wahba SA, El-Masry SA, Elhamid ER, Boseila SA, Ahmed NH, Ibrahim TS. Eating habits and lifestyles among a sample of obese working Egyptian women. Open Access Maced J Med Sci. 2015; 3:12–17. PMID: 27275190.

33. Lee HA, Lee WK, Kong KA, Chang N, Ha EH, Hong YS, Park H. The effect of eating behavior on being overweight or obese during preadolescence. J Prev Med Public Health. 2011; 44:226–233. PMID: 22020188.

34. Kang EY, Yim JE. Differences in dietary intakes, body compositions, and biochemical indices between metabolically healthy and metabolically abnormal obese Korean women. Nutr Res Pract. 2019; 13:488–497. PMID: 31814924.

35. Kim SH, Chun HJ, Choi HS, Kim ES, Keum B, Jeen YT. Current status of intragastric balloon for obesity treatment. World J Gastroenterol. 2016; 22:5495–5504. PMID: 27350727.

36. Buzga M, Kupka T, Siroky M, Narwan H, Machytka E, Holeczy P, Švagera Z. Short-term outcomes of the new intragastric balloon End-Ball^® for treatment of obesity. Wideochir Inne Tech Maloinwazyjne. 2016; 11:229–235. PMID: 28194241.

37. Keren D, Rainis T. Intragastric balloons for overweight populations 1-year post removal. Obes Surg. 2018; 28:2368–2373. PMID: 29497962.

38. Herve J, Wahlen CH, Schaeken A, Dallemagne B, Dewandre JM, Markiewicz S, Monami B, Weerts J, Jehaes C. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005; 15:864–870. PMID: 15978160.

39. Angrisani L, Lorenzo M, Borrelli V, Giuffré M, Fonderico C, Capece G. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006; 16:1135–1137. PMID: 16989695.

40. Stein EM, Silverberg SJ. Bone loss after bariatric surgery: causes, consequences, and management. Lancet Diabetes Endocrinol. 2014; 2:165–174. PMID: 24622720.

41. Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr. 2017; 8:511–519. PMID: 28507015.

42. Papageorgiou M, Kerschan-Schindl K, Sathyapalan T, Pietschmann P. Is weight loss harmful for skeletal health in obese older adults? Gerontology. 2020; 66:2–14. PMID: 31256166.

43. Fleischer J, Stein EM, Bessler M, Della Badia M, Restuccia N, Olivero-Rivera L, McMahon DJ, Silverberg SJ. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab. 2008; 93:3735–3740. PMID: 18647809.

44. Carrasco F, Ruz M, Rojas P, Csendes A, Rebolledo A, Codoceo J, Inostroza J, Basfi-Fer K, Papapietro K, Rojas J, et al. Changes in bone mineral density, body composition and adiponectin levels in morbidly obese patients after bariatric surgery. Obes Surg. 2009; 19:41–46. PMID: 18683014.

45. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007; 357:741–752. PMID: 17715408.

46. Heber D, Greenway FL, Kaplan LM, Livingston E, Salvador J, Still C. Endocrine Society. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010; 95:4823–4843. PMID: 21051578.

47. Maekawa S, Niizawa M, Harada M. A comparison of the weight loss effect between a low-carbohydrate diet and a calorie-restricted diet in combination with intragastric balloon therapy. Intern Med. 2020; 59:1133–1139. PMID: 32378654.

48. Papalazarou A, Yannakoulia M, Kavouras SA, Komesidou V, Dimitriadis G, Papakonstantinou A, Sidossis LS. Lifestyle intervention favorably affects weight loss and maintenance following obesity surgery. Obesity (Silver Spring). 2010; 18:1348–1353. PMID: 19834466.

49. Molin Netto BD, Earthman CP, Farias G, Landi Masquio DC, Grotti Clemente AP, Peixoto P, Bettini SC, von Der Heyde ME, Dâmaso AR. Eating patterns and food choice as determinant of weight loss and improvement of metabolic profile after RYGB. Nutrition. 2017; 33:125–131. PMID: 27474230.

Go to :

TOOLS

Similar articles